Trixeo Aerosphere Approved in Scotland as COPD Maintenance Therapy

Trixeo Aerosphere Approved in Scotland as COPD Maintenance Therapy

286240

Trixeo Aerosphere Approved in Scotland as COPD Maintenance Therapy

The Scottish Medicines Consortium (SMC) has approved AstraZeneca‘s triple combination therapy Trixeo Aerosphere as a maintenance treatment for chronic obstructive pulmonary disease (COPD). The approval specifically covers adults with moderate to severe disease who are not adequately treated by a combination of an inhaled corticosteroid (ICS) and a long-acting beta2-agonist (LABA), or by a LABA used in conjunction with a long-acting muscarinic antagonist (LAMA). Funding from the SMC will cover the costs of the newly approved treatment…

You must be logged in to read/download the full post.